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ABSTRACT
Poly-ADP ribose polymerase 1 (PARP1) is clinically important because of its 
synthetic lethality with breast cancer allele 1 and 2 mutations, which are causative 
for inherited breast and ovarian cancers. Biochemically, PARP1 is a single-stranded 
DNA break repair protein that is needed for preserving genomic integrity. In addition, 
PARP1 has been implicated in a veritable plethora of additional cellular pathways 
and thus its precise contribution(s) to human biology has remained obscure. To help 
address this deficiency, we utilized gene editing to construct genetically-null PARP1 
human cancer cells. We found a minor role for PARP1 in an alternative form of DNA 
double-strand break (DSB) repair, but only when these cells were deficient for the 
classical form of DSB repair. Despite being proficient for DSB repair, however, cell 
cycle progression defects and elevated endogenous DNA damage signaling were 
observed. These deficiencies were instead linked to telomere defects, where PARP1-/-  
cells had short telomeres that co-localized with markers of endogenous DNA damage 
and were compromised in their ability to escape a telomere-driven crisis. Our data 
suggest that while PARP1 does not participate significantly in DNA DSB repair itself, 
it does prevent the incidence of telomeric DSBs, which, in turn, can drive genomic 
instability.
INTRODUCTION
Poly-ADP ribose polymerase 1 (PARP1) is a 
ubiquitously and very abundantly expressed protein 
that post-translationally modifies target proteins with 
poly-ADP-ribose (PAR) moieties using a nicotinamide 
adenine dinucleotide (NAD+) as its biochemical substrate. 
Impressively, the sheer abundance of these post-
translational modifications in cells enabled researchers 
to discover such modifications prior to any information 
about the protein(s) responsible for their catalysis [1]. Of 
the 17 known PARP-domain-containing proteins (named 
PARP1 through PARP17, respectively), PARP1 is the most 
ubiquitous and most active isoform within eukaryotic 
cells, as its genetic deletion alone causes a dramatic 
loss in the amount of detectable PAR within cells [2]. 
Because PARP1 is the most abundant PARP and because 
PARylation is thought to be an important signaling 
process, it is perhaps not surprisingly that PARP1 has 
been implicated in a vast array of cellular processes, 
including cellular metabolism, cell cycle regulation, DNA 
replication, apoptosis and DNA break repair [3]. PARP1 
has been comprehensively studied biochemically in vitro 
and extensively by genetic knockout in vivo in a plethora 
of model organisms including mice [4], plants [5], and flies 
[6], as well as in chicken DT-40 cells [7]. These reports 
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generally conclude that PARP1 is important to preserve 
genomic integrity, and that it primarily participates in 
the repair of single-stranded DNA breaks (SSBs) [8]. To 
date there has been little phenotypic characterization of 
the genetic knockout of PARP1 in human somatic cells, 
as the field has either relied on RNAi knockdowns, or, 
primarily, by utilizing one of the many inhibitors available 
to PARP1 [9, 10]. The use of RNAi, however, rarely 
completely eliminates the very abundant PARP1 from a 
given cell, potentially obscuring relevant phenotypes. In 
a complementary fashion, PARP inhibitors generally have 
a dominant-negative effect on cellular PARP1 by trapping 
PARP1 at a SSB in a DNA-bound state [11–13]. Thus, the 
normal role of PARP1 in human cells remains somewhat 
poorly defined.
PARP1 is well-known because in its absence it 
exhibits synthetic lethality with breast cancer allele 
(BRCA)-deficient tumors [14, 15]. A prevailing theory 
(although other models have been proposed; see for 
example [16]) is that SSBs, which normally would 
be recognized for repair by PARP1, can accumulate 
over time and in a cancer cell such lesions would be 
converted to DSBs as a consequence of DNA replication 
[8]. Because BRCA1 and BRCA2 are required for the 
homology dependent repair (HDR) of these DSBs it has 
been postulated that it is this activity of BRCA1- and 
BRCA2-dependent repair that is required to preserve 
a viable level of genomic integrity in a PARP1-null/
inhibited background [17]. This pathway, while clearly 
relevant to explain the impact of PARP1’s absence on 
survival may, however, only be part of the story. For 
example, PARP1’s association with the replication fork 
is required for checkpoint kinase 1 (Chk1)-dependent 
activation of checkpoints that enable repair of DNA 
damage encountered by the replisome during S-phase 
[18]. In addition to signaling that a replication problem 
exists, PARP1 is also required for the resolution of certain 
replication lesions. For example, when a replication fork 
encounters lesions or chromatin obstacles it can stall. 
One way to resolve the stalled fork is to reverse it into 
a so-called "chicken-foot" structure [19]. Fork reversal 
facilitates stabilization of the fork and likely provides a 
window of opportunity to initiate lesion/obstacle bypass 
[20, 21]. PARP1 is required for this replication fork 
reversal and in PARP1's absence, this reversal is blocked 
[22]. In another example, PARP1 has been shown to 
regulate replication fork speed and the inhibition of 
PARP1 can cause replication fork acceleration and 
subsequent related genomic instability [23]. Therefore, 
the absence of PARP1 might cause a higher frequency of 
lesions during S-phase in addition to dysregulating the 
DNA damage responses.
Besides impinging upon HDR, PARP1 has been 
additionally implicated in the repair of DSBs by actively 
regulating non-homologous end joining (NHEJ). NHEJ 
involves the end-to-end ligation of two broken ends of 
double-stranded DNA, and can be sub-categorized into 
Classic NHEJ (C-NHEJ) or Alternative NHEJ (A-NHEJ) 
pathways. The C-NHEJ pathway is absolutely dependent 
upon the Ku70/86 heterodimer, a ring-shaped protein 
complex that binds the ends of broken DNA. The binding 
of the ubiquitously expressed and very abundant Ku 
heterodimer and subsequent activation of the C-NHEJ 
pathway can occur within seconds of a DSB occurring and 
is inherently repressive of A-NHEJ [24–26]. Accordingly, 
A-NHEJ is thought to be a minor or back-up repair 
pathway in normal cells [27, 28]. The hallmark of A-NHEJ 
is the use of microhomology, which also constitutes 
a molecular signature that remains at the site of repair, 
to facilitate the ligation of the two DNA ends [29]. One 
documented pathological role for A-NHEJ is its likely 
involvement in oncogenic chromosomal translocations in 
mice [30], although this is probably not the case in human 
somatic cells [31]. PARP1 has been implicated in the 
regulation of A-NHEJ, which was partially a consequence 
of discovering that PARP1-associated proteins, such as 
X-Ray Cross Complementing 1 (XRCC1), were required 
for A-NHEJ [32–35]. Finally, it has been suggested that 
the DNA binding activity of PARP1 could compete with 
Ku to enable A-NHEJ to occur in place of C-NHEJ [32], 
or repress Ku’s ability to access the DNA break [7]. In 
summary, PARP1 is clearly required for SSB repair and it 
appears to modulate DSB repair, although its role(s) in the 
latter pathway is still undefined.
One additional area of cellular biology where 
PARP1 may normally function is in telomere biology. 
Telomeres are the repetitive DNA:protein structures 
that serve to protect the ends of linear chromosomes 
from recognition as a DSB [36]. They are well known 
to regulate cellular aging, as they gradually shorten over 
time due to the end replication problem. Moreover, and 
of important clinical significance, the activation of a 
telomere re-elongation pathway is a key requirement 
for malignant progression [37]. Telomeres appear to 
be difficult regions of the genome to replicate [38], 
which is likely due to both the repetitive nature of the 
telomeric DNA, combined with their tendency to form 
G-quadruplex DNA [39, 40]. PARP1 has been identified 
as a telomere-binding protein and has been implicated in 
the regulation of telomere length maintenance [21, 41–
44]. Confusingly, the influence of PARP1 loss-of-function 
in the mouse has been reported to result in both telomere 
shortening [45] and to have no impact what-so-ever [46]. 
Similarly, there is a lack of agreement about the role of 
PARP1 in telomere length maintenance studies in human 
cells as the use of either RNAi against PARP1 [47] or 
inhibitors to PARP1 [47, 48] resulted in either telomere 
shortening [47] or lengthening [48]. Since some of these 
findings seem mutually exclusive and are likely due to 
differences in the experimental systems employed, a role 
for PARP1 in mammalian telomere maintenance is still 
controversial.
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To experimental address these issues, we utilized 
gene editing to generate PARP1-null human somatic cells. 
Human PARP1-null cells are viable but they exhibited 
spontaneous DNA damage, which tended to localize 
at telomeres, and was co-incident with short telomeres. 
Surprisingly, PARP1-null did not exhibit defects in 
DSB repair per se. Together, these data suggest that in 
human somatic cells PARP1's major role is in telomere 
maintenance and not DNA repair. This conclusion has 
significant relevance for clinical studies where the 
intervention of PARP1 activity is utilized.
RESULTS
Creation of PARP1-null cells
We utilized gene targeting in human HCT116 cells 
to functionally inactivate PARP1 by an exon-replacement 
strategy [49]. We designed a gene targeting construct in a 
recombinant adeno-associated viral vector (rAAV), such 
that correct targeting would result in the replacement of 
PARP1 exon 4 with a neomycin drug selectable marker 
(Figure 1A). Correct gene targeting was screened for 
by using PCR primer pairs with one primer that flanked 
the targeting construct combined with an internal primer 
specific to the drug selectable marker. After successful 
gene targeting, the drug selectable marker was removed by 
Cre-recombinase, thus generating a null allele. Two rounds 
of such targeting were required to generate a diploid null 
cell line, which was confirmed using PCR primers that 
flank exon 4 (Figure 1B; Supplementary Figure 1A). 
In a scenario where a gene exhibits no strong selective 
pressure, Mendelian genetics would predict that when 
targeting a heterozygous cell line, there is an equivalent 
50% chance of targeting either the already targeted allele 
(“re-targeting”) or targeting the second, still functional 
allele. During the second round of PARP1 targeting, only 
3 of 72 correctly targeted clones resulted in the loss of 
the second PARP1 allele (i.e., 69 of 72 clones were re-
targeted) (Table 1). This exceptional disequilibrium in the 
gene targeting frequency is usually a hallmark of genes 
that provide a significant growth disadvantage when 
absent [50–52]. Thus, although the isolation of three 
independent PARP1-null clones was unequivocal evidence 
that PARP1 is not essential in human HCT116 cells, the 
frequency with which these clones were obtained was also 
an indication that PARP1 has an important role in human 
cellular biology.
We next sought to complement these cells with 
either an empty vector, or a wild type (WT) PARP1 
cDNA, which was integrated randomly into the genome 
by a PiggyBac transposon system [53]. The restoration 
of PARP1 protein in the null cells was confirmed by a 
western blot analysis (Figure 1C; Supplementary Figure 
1C). A series of complemented clones in which PARP1 
was either under- (“low”), ~normally- (“medium”) or 
over- (“high”) expressed were generated for each of 
the three null cell lines (Figure 1C; Supplementary 
Figure 1C). In order to validate that the complemented 
clones contained active protein, a PARylation assay 
was performed, which confirmed both the successful 
ablation of PARP activity in the null cells, as well as their 
functional complementation (Figure 1D). Interestingly, 
even the lowest levels of complementing PARP1 
expression could fully rescue PARP activity (Figure 1D). 
An obvious phenotype of the PARP1-/- cells was their 
slow growth, as they exhibited an almost 50% reduction 
in doubling time (Figure 1E; Supplementary Figure 1B). 
Again, this phenotype could be completely rescued by the 
re-expression of even low levels of PARP1 (Figure 1E). 
In summary, these data compellingly demonstrated that 
PARP1 is not essential in human somatic cells, but that its 
absence results in significant deficits to both replication 
and survival.
PARP1-null cells accumulate in G2 of the cell 
cycle
In order to better understand the cellular growth 
defect, we investigated whether this was correlated 
with deficits in cell cycle progression. In asynchronous 
populations, the null cells exhibited a modest increase in 
the number of cells in G2, compared to both WT and the 
complemented cells when the DNA content of these cells 
was analyzed using propidium iodide staining (Figure 
2A). In order to better understand this G2 accumulation, 
cells were synchronized at the G1/S transition point with 
serum starvation, followed by an overnight incubation in 
thymidine (in the presence of serum), which transiently 
arrested the cells at the G1/S transition. After releasing 
the cells into standard media, the cell cycle profile of 
the cells was determined (Figure 2B). The PARP1-null 
cells progressed through the cell cycle at approximately 
the same rate as either WT or complemented cells, but 
after S-phase, dramatically accumulated in the G2 phase. 
This is best exemplified by the amount of PARP1-null 
cells remaining in G2 (36.4%) at the 12 hr time point, in 
comparison to the rest of the genotypes (12% to 18%), 
which were successfully able to continue through mitosis 
and into the subsequent G1 phase (Figure 2B). The 
accumulation of PARP1-null cells in the G2-phase of the 
cell cycle, suggested that the cells were experiencing an 
elevated level of DNA damage that was, in turn, activating 
the G2/M checkpoint. Consistent with this interpretation, 
PARP1-null cells had elevated levels of p53, with respect 
to control lines (Figure 2C; Supplementary Figure 2).
PARP1 modulates, but is not required for, 
A-NHEJ
The spontaneous elevation of p53 expression in 
asynchronously growing PARP1-null cells suggested that 
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the absence of PARP1 was contributing to an accumulation 
of DNA damage. Given the aforementioned reports of 
PARP1’s role in DSB repair, we thus next measured the 
cells’ capacity for this activity. Cells were transfected 
with a linearized plasmid-reporter, pDVG94, allowed 
48 hr to enact repair, and then circularized plasmids 
were recovered from the transfected cells. Cells have 
two options to repair the linearized plasmid. They can 
simply re-ligate the ends together, which is indicative 
of C-NHEJ and which can be quantitated as a ~180 bp 
PCR product when primers flanking the repair junction 
are utilized (Figure 3A). Alternatively, cells that utilize the 
6 bp of microhomology present at the linearized ends to 
repair the plasmid create a diagnostic restriction enzyme 
recognition site, BstxI. Cleavage of the PCR products 
generated with primers flanking the repair junction with 
BstXI generates a 120 bp fragment (and a 60 bp fragment) 
and the appearance of this product(s) versus the 180 bp 
product enables a relative measure of A-NHEJ versus 
C-NHEJ activity (Figure 3A) [54]. In wild type cells 
Figure 1: Construction and confirmation of PARP1-null cells. (A) PARP1 knockout HCT116 cells were constructed by rAAV-
mediated gene targeting. Exon replacement of the 4th exon (open green rectangle) of the PARP1 gene with a floxed, Neo-cassette (orange 
rectangle) occurs by HDR, which can be subsequently removed by Cre-recombinase to result in the removal of the 4th exon, causing a 
frame-shift mutation. Two rounds of gene targeting were performed to eliminate both alleles in this diploid cell line. Red arrows depict PCR 
primers used to monitor gene status. Red triangles represent LoxP sites. (B) PCR confirming the conversion of one wild-type (WT) allele 
to a null allele in a PARP1+/- cell and the conversion of both wild-type alleles to null in PARP1-/- null cells. (C) Western blot confirmation 
of the loss of PARP1 expression and confirmation of complementation of the null cells with PARP1 protein. (D) a PARP1 activity assay 
demonstrates that the wild type and indicated complemented cells exhibited WT-levels of parylation, while the null cells lacked such 
activity. EV is indicative of cells complemented with an empty vector. (E) growth curve depicting that the absence of PARP1 results in a 
slow growth phenotype.
Table 1: PARP1 gene targeting results
Desired Genotype Targeted/Random Insertion Number of Targeted Clones
Expected Number of 
Desired Clones
Parp1+/- 23/96 23 Not Applicable
Parp1-/- 72/139 3 36
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approximately 15% of the repair products could be 
ascribed to A-NHEJ (Figure 3B, 3C). As a positive control 
we also analyzed the same plasmid rejoining in a cell line 
defective in DNA Ligase 4 (LIG4) [55]. As expected [24, 
25] these cells carried out virtually exclusively (97%) 
A-NHEJ (Figure 3B, 3C; Supplementary Figure 3). 
Consistent with previous studies [32–35], the PARP1-null 
cells showed a statistically significant deficit in A-NHEJ 
(Figure 3B, 3C). The deficit, however, was rather small 
(<2-fold), and importantly could not be phenocopied by 
treating wild type cells with a PARP1 inhibitor, olaparib 
(Supplementary Figure 3). To clarify these results, we next 
induced A-NHEJ activity by pretreating cells with the 
DNA-PKcs inhibitor, NU7441 [56], which should increase 
the relative amount of A-NHEJ by inhibiting the Ku/DNA 
PKcs-dependent C-NHEJ pathway. All genotypes, except 
again as anticipated, LIG4-null cells, showed enhanced 
A-NHEJ activity in the presence of NU7441 (Figure 3B, 
3C). Importantly, however, the PARP1-null cells showed 
increases in A-NHEJ activity comparable to the wild-
type and complemented clones (Figure 3B, 3C). Most 
provocatively, the treatment of LIG4- and DNA-PKcs-
null clones with olaparib was completely ineffective in 
inhibiting A-NHEJ (Supplementary Figure 3). Thus, the 
absence of PARP-1 did not affect the cellular capacity 
for A-NHEJ in all situations where A-NHEJ activity was 
either genetically or chemically enhanced.
Since previous models had suggested that PARP1 
may compete for DSBs with the Ku heterodimer [7, 32] 
we carried out an additional experiment to test whether 
or not the converse of our conclusion that PARP1 activity 
might be C-NHEJ dependent was true: i.e., whether the 
absence of PARP1 affects C-NHEJ. PARP1-/- cells and 
relevant controls were transfected with the pEGFP-Pem1-
Ad2 reporter, which measures C-NHEJ activity [57]. As 
expected, a LIG4-null cell line showed greatly reduced 
activity in this assay (Figure 3D; Supplementary Figure 
4). In contrast, the presence or absence of PARP1 had no 
effect on the levels of C-NHEJ in the various cell lines 
(Figure 3D; Supplementary Figure 4). Thus, we conclude 
that PARP1 does not participate (significantly) in either 
C-NHEJ- or A-NHEJ-mediated DSB repair in human 
cells.
PARP1 is required for proper telomere 
maintenance
The above experiments demonstrated that while 
PARP1-null cells seemed to be sensing significant 
amounts of DNA damage or stress, they had only 
mild deficits in the repair of such damage. Thus, we 
hypothesized that this damage might rather be associated 
with stalled or stressed DNA replication forks [23]. One 
region of particular interest was telomeres [58], as PARP1 
had been identified as a telomere-binding protein, and 
some previous reports of telomere shortening have been 
associated with PARP1 inhibition or inactivation [41–44]. 
To explore this possibility, we — in a blinded fashion 
— analyzed 50 randomly-selected metaphase spreads 
from wild type and PARP1-/- cells for the presence of 
Figure 2: PARP1-null cells exhibit a G2-growth arrest. (A) the DNA content of asynchronously growing cells exhibited a modest, 
constitutive G2 cell cycle accumulation. (B) a time course study of thymidine-block synchronized cells. After release, all cells appeared to 
progress through S-phase at approximately the same rate, but many PARP1-null cells did not progress through mitosis, but rather exhibited 
a G2/M cell cycle accumulation. (C) Western blot evidence for increased p53 expression in PARP1-/- cells. Ku70 was used as a loading 
control (Supplementary Table 2).
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signal-free ends. After un-blinding the images, 26 were 
wild type, and 23 were from PARP1-/- cells (one image 
was discarded due to poor quality). Signal-free ends 
are operationally defined as telomeres that are so short 
that they do not hybridize well to a telomere-specific 
[(A2TC3)3] fluorescent protein:nucleic acid (PNA)-probe 
(Figure 4A, 4B). Cells with normal length telomeres 
will generally yield a uniform staining pattern with 4 red 
fluorescent spots — one at the ends of each chromatid 
(Figure 4A). In contrast, PARP1-/- metaphases exhibited 
variable staining and a significant increase in the number 
of chromatid ends where no hybridization signal was 
visible whatsoever (Figure 4A, 4B). Thus, PARP1-/-  
cells appeared to have at least a subset of very short 
telomeres. Deficits in telomere length were confirmed by 
Southern blotting. Initial screening of several subclones 
of WT, PARP1-/-, and PARP1-/-:+PARP1 complemented cells 
demonstrated that the null cells (median telomere length 
of 2.5, 2.1, and 2.3 kb for the three PARP1-null clones) 
had in general shorter telomeres than WT cells (median 
telomere length of 5.0 kb; Figure 4C). We did note that this 
phenotype was variable, i.e. some null clones were shorter 
than others, and most of the complemented clones did not 
restore the telomere length to WT levels. We attributed 
this to the inherent (and unfortunate) consequence of the 
clonal variation in telomere length that exists in human 
Figure 3: The impact of the absence of PARP1 on A- or C-NHEJ. (A) schematic of the pDVG94 plasmid. (B) the indicated 
cell lines were treated with 1 μM of the DNA PKcs inhibitor, NU7441, for 4 hr, and then transfected with linearized pDVG94. Cells were 
allowed 24 hr to repair the linearized template (still in the presence or absence of inhibitor), then plasmids were extracted, and the region 
spanning the cut site was amplified by PCR, followed by digestion with BstXI. The restriction enzyme products were then analyzed by 
agarose gel electrophoresis. The gel fragments corresponding to either C-NHEJ- or A-NHEJ-mediated repair migrate either at 180 or 120 
bp, respectively. (C) quantitation of three experiments similar to panel B. PARP1-/- cells exhibited a significant (p = 0.01) ~2-fold reduction 
in baseline A-NHEJ activity but were not statistically different from wild type cells under induced conditions. (D) the indicated cell lines 
were transfected with linearized pGEM-Ad2-EGFP plasmid and subjected to flow cytometry analysis. Only DNA LIG4-/- cells exhibited a 
significant defect in DNA repair.
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somatic cells. Thus, to properly analyze the capability 
of PARP1 expression to complement the PARP1-/- cells, 
we created more independent complemented clones, 
along with empty vector clones, and re-screened their 
telomere lengths. While all (6/6) of the empty vector 
(EV)-containing clones had telomeres that were shorter 
than the PARP1-null parental cell line, only 5 of 17 of the 
PARP1-expressing clones were shorter. Correspondingly, 
12 of the 17 PARP1-complemented clones remained at 
the parental (null) size or in a few cases actually showed 
telomere elongations, albeit with one exception, not to 
wild type length (Figure 4D). Thus, we concluded that 
PARP1 prevents abnormal telomere shortening, but it does 
not significantly contribute to telomere lengthening.
Given the aforementioned observed G2/M cell 
cycle arrest, we probed for any connection between the 
spontaneous DNA damage and the shortened telomere 
phenotype. Specifically, we utilized an IF-FISH assay, 
which combines immunofluorescence of proteins with 
FISH to co-visualize proteins and DNA sequences. We 
performed this assay in the various cell lines for both 
telomeric DNA and 53BP1, a common marker of DNA 
DSBs [59, 60]. In PARP1-null cells there was a higher 
spontaneous frequency of 53BP1 foci (Figure 5A, 5C), 
and these foci significantly (p > 0.05) co-localized with 
telomeric DNA (telomere dysfunction-induced foci, TIFs; 
Figure 5A, 5B). Importantly both the elevated 53BP1 
foci and the TIFs could be completely suppressed by the 
re-expression of PARP1 in the PARP1-null cells (Figure 
Figure 4: PARP1-null cells exhibit telomere dysfunction. (A) PARP1-null cells have an increased frequency of signal free ends. 
Metaphase spreads were prepared from the indicated cell lines and then stain with a telomeric PNA probe (red spots) and then counter-
stained with DAPI (blue). (B) the number of signal free ends from ~25 such metaphases was quantified for each genotype. (C) a TRF 
analysis of the telomere length of the indicated cell lines. For many of the cell lines, independent subclones were isolated and these are 
indicated by the clone number. Genomic DNA from the indicated cell lines was prepared, digested to completion with frequent cutting 
restriction enzymes and the residual DNA was electrophoresed onto an agarose gel and then transferred to nitrocellulose. The blot was 
subsequently hybridized with a radioactive telomeric probe. Since telomere length is variable from chromosome end to chromosome end 
and from cell to cell, a smear results. The mid-point of the telomeric smear is indicated with a green point. (D) PARP1-/- cells have short 
telomeres, which can be rescued by complementation. In order to evaluate the clonal effect of telomere length, we derived empty vector 
containing (yellow rectangles), and complemented clones (green rectangles), from a given parental null clone (red rectangle) and then 
determined their telomere length by TRF analysis as shown in (C). The average telomere length by as determined by densitometry is shown.
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5). Together, these data demonstrated that the telomeres 
of PARP1-null cells are short and that they are prone to 
incurring significant amounts of DNA damage.
PARP1 affects cellular immortalization
To confirm and extend the conclusion that PARP1-null 
cells have dysfunctional telomeres, we next tested whether 
PARP1-null cells could survive a “telomere challenge”. In 
these experiments, a dominant negative telomerase (DN-
hTERT) that suppresses endogenous telomerase activity 
was expressed in the cells. DN-hTERT expression results 
in telomere shortening and generally forces the cells into 
a “crisis” that is very much akin to the classic telomeric 
crisis that primary cells must overcome to enable cellular 
immortality [61]. Following the replicative erosion induced 
by the expression of the DN-hTERT, cells normally undergo 
a period of slow growth and genetic instability due to the 
resulting shortened telomeres, but ultimately re-establish 
wild-type telomerase expression and telomere maintenance 
[62, 63]. Indeed, when DN-hTERT was expressed in wild 
type cells, all of clones (15/15) analyzed escaped the 
subsequent crisis and continued to proliferate for at least 
80 days, (or in some cases 100 days), after which point the 
experiment was intentionally terminated (Figure 6A). In 
stark contrast, only 1 of 14 PARP1-null clones was able to 
escape and immortalize (Figure 6B). To expand upon this 
observation, the PARP1-null clones were also subjected to 
a single telomere length analysis (STELA) after various 
population doublings (PDs) following the expression of 
DN-hTERT. STELA is a PCR-based technology using 
sub-telomeric anchored primers and linker primers 
ligated onto the ends of telomeres to analyze, at the single 
molecule level, the length of individual telomeres [62, 64]. 
Consistent with the TRF analysis (Figure 4C), the STELA 
analysis confirmed that the average telomere length of the 
PARP1-null parental population was a relatively short 2.44 
kb (Figure 6C). DN-hTERT expression reduced this length 
further with many of the clones (#3, #7, #8, #10 and #12 
are shown) having mean lengths between 0.86 to 1.50 kb 
after only ~20 PDs. Interestingly, the single PARP1-null 
clone that survived (clone #7) also showed early on (PDs 
20.1 to 24.5) a significant reduction in telomere length 
indistinguishable from the clones that died although after 
PD 62.2 its telomeres began to subtly elongate. Telomere-
specific single molecule PCR can also be used to detect 
telomere fusion events [62, 64]. No fusions were detected 
in the PARP1-null cell line in the absence of DN-hTERT 
Figure 5: Spontaneous DNA damage foci in PARP1-/- cells co-localize with telomeres. (A) the indicated cells were 
immunostained for 53BP1 (green), fixed, and then subsequently probed for telomeric DNA with a PNA FISH probe (red) and for total DNA 
with DAPI (blue). PARP1-/- cells had an elevated level of 53BP1 foci, which tended to colocalize with telomeric DNA. (B) The number 
of telomeric ends and overlapping 53BP1 foci (TIFs) on a per cell basis from images similar to panel (A) were averaged and graphed 
+/-1 standard deviation. PARP1-/- cells had a statistically significant increase in the frequency of TIFs compared to the control cell lines. 
(C) Quantification of just 53BP1 foci/cell on a per cell basis from images similar to panel (A) were averaged and graphed +/-1 standard 
deviation. PARP1-/- cells had an increased level of endogenous 53BP1 foci, which was indicative of DNA damage.
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Figure 6: PARP1-/- cells are severely compromised in surviving telomeric stress. (A) growth curves plotting population 
doublings (PD) and days in culture. Each line represents an independent subclone. For some of the wild type clones the experiment was 
intentionally terminated after 80 days and for others only after 120 days. (B) growth curves plotting PD and days in culture for PARP1-null 
cells; only a single subclone (green line) survived beyond 40 days. (C) Top. STELA of the 17p telomere. The PD from the point of single 
cell cloning is shown above, while the mean (in kb) of the telomere length profiles is shown below. Bottom. Single-molecule telomere 
fusion analysis, using oligonucleotide PCR primers targeted to XpYp, 17p and the 21q family of related telomeres at the PD points as 
indicated.
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expression (Figure 6C), which suggested that the increased 
SFEs (Figure 4B) and TIFs (Figure 5B) observed in this 
population was apparently not sufficient to induce telomeric 
fusion events. In striking contrast, telomeric fusions were 
detected with all of the PARP1-null clones expressing 
DN-hTERT although fewer translocations were detected 
in clone #7, which was the clone that ultimately survived 
(Figure 6C). Thus, in agreement with our end-joining data 
(Figure 3) PARP1-null cells apparently had no difficulty 
ligating their uncapped telomeres together. In summary, 
these data demonstrated that the telomere dysfunction 
observed in PARP1-null cells while insufficient to induce 
telomere fusions spontaneously, severely compromised the 
ability of the cells to re-establish telomere maintenance in 
the face of gradual telomere erosion.
DISCUSSION
PARP1 has been the subject of intense study 
in multiple model organisms. In spite of this, the 
molecular mechanism of PARP1 action in certain cellular 
transactions is still unclear. For example, while PARP1 
loss-of-function mutations were initially discovered to be 
synthetically lethal with BRCA1 and BRCA2 mutations 
[14], some cancer patients with such mutations have not 
benefited from PARP1 inhibition [65], and many tumors 
that are BRCA1- and BRCA2-proficient can likewise be 
sensitized by PARP1 inhibition [66, 67]. Thus, while there 
is no dispute that PARP1 inhibition can cause synthetic 
lethality in BRCA1 and BRCA2 mutant tumors, the 
molecular mechanism of that lethality is yet to be fully 
elucidated. One explanation for this ambiguity is that 
a common feature of PARP1 inhibitors is that they can 
have dominant-negative effects in cell lines that contain 
the target protein. While the results drawn from these 
experiments are not in any way invalid, it can be difficult 
to discern the effect of non-functional protein versus the 
absence of that protein. Here, we genetically ablated 
PARP1 in a BRCA1- and BRCA2-positive cancer cell line, 
HCT116, to better understand the role of PARP1 in an 
otherwise normal, albeit oncogenic, generic background.
HCT116 cells were selected as the cellular model for 
these experiments because they are diploid, have a stable 
karyotype and are wild-type for most DNA repair, DNA 
checkpoint and chromosome stability genes (reviewed 
in [68]). With that said, it should be noted that HCT116 
cells are also mismatch repair defective and because of 
this deficiency the cells (especially if cultured for a long 
period of time — something that we explicitly avoid) have 
the tendency to accumulate genetic mutations [69]. In spite 
of this caveat, HCT116 cells have been utilized more than 
any other human cell line for carrying out reverse genetic 
gene editing experiments and have been proved to provide 
data that is comparable to many other human cell lines, 
including several that are non-tumorigenic [68]. Thus, while 
the findings presented here are potentially only relevant to 
this singular cancer cell line, we are confident the results 
accurately reflect the role of PARP1 in human cells.
Importantly then, in the PARP1-null cells we found 
little evidence of significant DSB repair defects, but rather 
observed an increase in cells accumulating in the G2/M 
checkpoint, likely as a result of endogenous DNA damage/
short telomeres. We further showed that the DSBs that 
do appear tend to occur in telomeric DNA, which while 
likewise contributing to checkpoint activation, further 
limit the cell’s proliferation and subsequent ability to 
handle telomere stress.
One novel finding from these studies is the 
demonstration that PARP1 is a non-essential gene in human 
somatic cells. Our ability to isolate three independent 
PARP1-null clones is unequivocal evidence that PARP1 
is not required for survival. With that said, there has 
never been, to our knowledge, a human patient described 
anywhere in the world who is/was PARP1-null. Indeed, our 
own gene targeting studies argue strongly that PARP-1, 
while not technically essential, is nonetheless so important 
that the development of a viable human is unlikely. Gene 
targeting is a completely egalitarian process and either allele 
in a diploid cell is as equally likely to be modified as the 
other [68]. During the second round of PARP1 targeting 
however, 69 of 72 clones were re-targeted and only 3 of 72 
correctly targeted clones resulted in the loss of the second 
PARP1 allele (Table 1). This exceptional disequilibrium 
in the gene targeting frequency is a hallmark of genes that 
provide a significant growth disadvantage when absent 
[50–52]. The fact that any viable clones were obtained could 
be attributed to the possibility that the PARP proteins are 
functionally semi-redundant (discussed further below), and 
in rare cases other PARPs, such as PARP2 and PARP3 [70], 
could minimally fulfil the essential role of PARP1 in cells, 
although we note that there was no (detectable) PARylation 
activity in the PARP1-null cells (Figure 1D). Our subsequent 
demonstration that there are significant deficits in PARP1-
null cells with telomere maintenance are completely 
consistent with this conclusion. Thus, the three independent 
PARP1-null clones notwithstanding, we predict that in the 
context of organismal development that PARP1 will be 
essential and that PARP1-null patients will not be identified.
An additional key finding we present is the lack 
of a significant effect on A-NHEJ caused by the absence 
of PARP1 (Figure 3; Supplementary Figure 3). While 
it is compelling that PARP1 inhibition can result in 
diminished end-joining activity in many cell types, we 
suggest that PARP1 is not a critical A-NHEJ gene. Such 
mischaracterization has historical precedent, as PARP1 
has been previously mislabeled as a core BER gene [8]. 
This was originally suggested by the finding that PARP1-/- 
murine embryonic fibroblasts (MEFs) were hypersensitive 
to BER-sensitizing alkylating agents, such as methyl-
methane sulfonate [71]. However, subsequent investigation 
demonstrated that the inhibition of PARP1 was simply 
either trapping a BER-intermediate [12] or modulating 
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the terminal ligation step [72] and that PARP1 was not 
an integral component of the BER machinery. Another 
potential contributor to the confusion regarding the role 
of PARP1 in A-NHEJ (and other cellular processes) is that 
PARP-inhibitors are often presumed to only inhibit PARP1, 
when the opposite is truer. Thus, since virtually all PARP 
inhibitors utilize NAD+ analogs to competitively bind and 
inhibit PARP enzymes, it is unsurprising that common 
inhibitors such as olaparib bind and inhibit most PARP 
family members, including PARP2 and PARP3, with equal 
affinity [73]. This is especially pertinent given the evidence 
that the PARPs have (at least partial) redundancies in their 
activities. For example, while PARP1-null mice are viable, 
PARP1-/-:PARP2-/- mice are not viable [74]. Moreover, 
singly mutant PARP2-/- mice exhibit a modest radiation 
sensitivity, indicative of defects in DNA repair, which 
are presumed to overlap with PARP1 [74]. Similarly, 
PARP3 has been implicated in DNA repair and telomere 
integrity [75]. These functional redundancies have been 
biochemically confirmed (see for example, [76]) including 
most recently by mutating the NAD+ binding domains of 
PARP1, PARP2, and PARP3 and utilizing correspondingly 
distinct NAD+ analogs, which allowed the targets (some 
of which were overlapping) of each PARP to be identified 
[77]. Such partial functional redundancies underscore the 
necessity for careful genetic studies to affirm the role of 
each PARP in various cellular processes, in lieu of making 
general claims with nonspecific inhibitors.
Here, we hypothesize that the purported role of 
PARP1 in A-NHEJ may in fact be due to a combination of 
its SSB repair activity and perhaps non-redundant activities 
of other PARPs susceptible to inhibition. The lack of a 
strong A-NHEJ phenotype for PARP1-/- human cells is 
consistent with emerging molecular evidence detailing the 
mechanism of A-NHEJ itself. Rather than a discrete sub-
pathway of NHEJ, it now appears that A-NHEJ may be 
a HDR sub-pathway which is engaged when canonical 
HDR fails to find the appropriate homologous template for 
proper repair [78]. Several independent reports support this 
emerging theory. First, the requirement for microhomology 
at the ligation junction conceptually underlies a requirement 
for some degree of DNA-resection, followed by homology 
searching, both of which are much more akin to HDR 
than NHEJ. Moreover, reports have confirmed that the 
homology searching in A-NHEJ is dependent on the 
Meiotic Recombination 11/Radiation Sensitive 50/Nijmegen 
breakage syndrome 1 (MRE11/RAD50/NBS1; MRN) 
complex and C-terminal interacting protein (CtIP) [79, 80], 
as well as BRCA1 [81], all of which are canonical HDR 
genes. In addition, the kinetics of A-NHEJ are similar to 
HDR and distinct from C-NHEJ [82]. In toto, these reports 
are consistent with A-NHEJ being a sub-pathway of HDR. If 
this model is true, then the key regulatory A-NHEJ genes are 
more than likely to be the upstream HDR repair genes, rather 
than PARP1. Thus, we suggest that while PARP1 inhibition 
affects A-NHEJ activity in certain experimental models 
[83–85], it is not a canonical A-NHEJ gene. With this said, a 
small, albeit significant and reproducible, deficit in A-NHEJ 
activity was observed in PARP1-null cells — intriguingly 
however, only when they were proficient for DNA-PKcs 
(and therefore presumably proficient for C-NHEJ) (Figure 
3, Supplementary Figure 3). This deficit is more compatible 
with the more widely accepted models of A-NHEJ being a 
salvage pathway for ineffective C-NHEJ [27]. Needless to 
say, these models are not mutually exclusive and A-NHEJ 
could be the salvage pathway for both unsuccessful HDR 
and C-NHEJ. In this scenario, the presence (or absence) of 
PARP1 seems to impact the C-NHEJ salvage subpathway 
more than the HDR one. All of these models clearly deserve 
further experimentation/testing.
The role of PARP1 in telomere maintenance 
has remained an ambiguous, yet intriguing, concept. 
To date, the majority of work has described a role for 
PARP1 in mediating aberrant DNA repair at uncapped 
or damage telomeres, specifically causing the fusion of 
sister-chromatid telomeres [41, 81, 86, 87]. Thus, these 
reports have implied that PARP1 is actively repressed 
from binding to functional telomeric DNA. Yet, other 
reports have indicated a functional interaction with 
Telomere Recognition Factor 2 (TRF2), a principal 
component of the Shelterin complex [43]. PARP1 was also 
independently identified as a Shelterin binding protein by 
an unbiased mass-spectroscopy approach [44]. Consistent 
with those reports is the fact that PARP1 possess a 
canonical TRF2-interacting motif (F/Y-X-L-X-P): 
737YTLIP741 [88]. Reports of the role of PARP1 in MEFs 
are conflicting: certain PARP1-/- MEFs exhibit telomere 
shortening [42, 43], while in other studies there was no 
appreciable telomere phenotype [46]. Our data strongly 
suggest that one of the critical roles of PARP1 in human 
somatic cells is to maintain telomeric integrity. The most 
likely scenario is that PARP1 is preferentially recruited to 
telomeres, through its interaction with Shelterin, to help 
regulate the repair of SSBs caused, or encountered by, the 
DNA replication machinery [16]. Thus, the absence of 
PARP1 could result in the conversion of these telomeric 
SSBs to DSBs by DNA replication, resulting in a telomere 
shortening phenotype, DNA DSB signaling, and genomic 
instability — all of which we observed (Figures 4 and 5). 
Importantly, we do not suggest that PARP1 is a telomere 
lengthening protein; it does not function akin to telomerase 
and the re-introduction of PARP1 to PARP1-null cells 
did not result in extensive telomere elongation. Rather, 
we posit that the presence of PARP1 allows for longer 
telomeres to maintain their stability. This is evidenced by 
the variation we observed in the extent of the telomere 
length restoration in PARP1-null complemented cells. The 
absence of PARP1 does cause telomere shortening (albeit 
indirectly), but the re-expression of PARP1 in these cells 
only allowed cells to stabilize the longer telomeres that 
were subsequently generated by the clonal variation in 
telomerase-positive cancer cells (Figure 4). Thus, we 
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conclude that PARP1’s primary role is in preserving 
telomere length maintenance.
Recently, our laboratories have examined the 
contributions of the C-NHEJ and A-NHEJ pathways in 
facilitating the fusion of short dysfunctional telomeres 
in human cells following replicative erosion [62, 63]. 
These studies identified DNA Ligase 3 (LIG3) — a gene 
universally regarded as being A-NHEJ-specific — as 
being essential for cells to escape the subsequent crisis 
and survive [62]. Here we utilized this assay to determine 
if PARP1-null cells also have a role in telomere length 
maintenance, hypothesizing that if PARP1 was required 
for A-NHEJ, it would phenocopy the requirement for 
LIG3 in immortalization. Very surprisingly, we were able 
to demonstrate that although PARP1 had little impact 
on A-NHEJ (Figure 3) it nonetheless nearly completely 
phenocopied the requirement for LIG3 in immortalization 
(Figure 6). These results demonstrated that PARP1 and 
LIG3 do indeed share a strong genetic interaction for 
cellular immortalization caused by telomere shortening. At 
the same time, however, these results also contradicted our 
hypothesis and demonstrated that that genetic interaction 
is unlikely related to A-NHEJ. This conclusion suggests 
that SSB repair (a pathway that PARP1 and LIG3 also co-
participate in) may be the culprit. We suggest that ssDNA 
lesions may accumulate in telomeric sequences (perhaps 
during the replication of the telomere) and the inability to 
accurately repair these lesions may facilitate chromosomal 
fusions. Although further experimentation will clearly be 
needed to clarify this issue the near inability of PARP1-
null cells to survive crisis (Figure 6) is completely 
consistent with our posited role for PARP1 in maintaining 
telomeric homeostasis.
Finally, we note that our data have clinical 
implications. Thus, PARP1 inhibitors are currently being 
extensively utilized in the clinic. Our demonstration 
here that the absence of PARP1 in human cells leads to 
aberrant telomere maintenance suggests that there may 
be significant long-term repercussions to the chemical 
inhibition of PARP1 in human cells that might not be 
immediately evident.
MATERIALS AND METHODS
Cell culture
HCT116 cells were purchased from the ATCC and 
maintained in McCoy’s 5A media supplemented with 10% 
FBS, 1% glutamine, and 1% penicillin/streptomycin. Cells 
were maintained in 10 cm plates and passaged every 3 
to 5 days. To initiate telomere erosion in HCT116 cells 
expressing DN-hTERT, the cells were transduced with 
amphotropic retroviral vectors containing a DN-hTERT 
cDNA [89] as described [90]. For cell synchronization 
studies, cells were cultured for 16 hr in McCoy’s 5A media 
containing 0.1% FBS, and subsequently grown in 2 mM 
thymidine for 24 hr. Cells were then released into complete 
McCoy’s 5A media and collected by trypsinization at the 
indicated times.
Gene targeting and PARP1 knockouts
The PARP1 gene knockout by exon replacement 
with rAAV was performed by rAAV-mediated gene 
targeting. Briefly, homology arms were constructed by 
PCR (Supplementary Table 1), flanked by a LoxP-IRES-
Neo-LoxP cassette, and ligated into an rAAV production 
vector. Producer 293-AAV cells were co-transfected 
with pAAV Helper and pAAV Rep/Cap, as described 
[91]. Target wild type HCT116 cells (1 x 105) were 
plated approximately 24 hr prior to rAAV-infection in a 
6-well plate. Cells were infected with virus-containing 
media, and 48 hr-post infection, the cells were single-cell 
subcloned in the presence of 0.5 mg/mL G418. Drug-
resistant colonies were collected ~2 weeks after infection, 
and the correct replacement of exon 4 was screened by 
PCR (Supplementary Table 1). Correctly targeted clones 
were plated (1 x 105) and infected with an adenoviral 
vector expressing the Cre-recombinase to remove the 
drug selectable marker by Cre-recombination. Cells were 
again single cell sub-cloned, and screened for correct 
Cre recombination events by PCR flanking exon 4. This 
process was repeated stepwise to inactivate the second 
PARP1 allele.
DNA repair assays
All transfections were performed on 5 x 105 cells 
with Lipofectamine 3000 in 6-well plates, which had been 
subcultured 24 hr prior to transfection. For the A-NHEJ 
reporter assay, we transfected 2.5 μg of linearized 
pDVG94 into target cells and allowed 24 hr for repair. The 
cells were subsequently collected by trypsinization, and re-
circularized plasmids were recovered using conventional 
small-scale plasmid DNA isolation, as proper repair of the 
linearized junction by human cells creates a circularized 
DNA product which is accordingly recoverable. Repaired 
DNA junctions were PCR amplified using the FM30 and 
DAR5 primers [54]. PCR products were then digested 
with the BstXI restriction enzyme. Digested PCR products 
were resolved by electrophoresis on a 6% polyacrylamide 
gel. The gel was then stained with SybrGold and imaged 
on a Typhoon FLA 9500 imager.
For the FACS-based NHEJ reporter assay, we first 
subcloned the ISce-I coding sequences from an expression 
plasmid [92] and added a C-terminal T2A-mCherry 
epitope by fusion PCR. We then cloned this expression 
construct into a pcDNA 3.1 expression vector. For each 
NHEJ FACS assay, 1.25 μg of pGEM-Ad2-EGFP was co-
transfected with the ISce-I-T2A-mChery plasmid into 5 
x 105 cells in 6-well plates. 24 hr following transfection, 
cells were collected by trypsinization, fixed with 4% 
formaldehyde, and subjected to FACS analysis.
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Telomere/terminal restriction fragment (TRF) 
assay
Genomic DNA was extracted from ~1 x 107 cells, 
and 50 μg of genomic DNA was digested with HinfI 
and RsaI, as described [93]. For each sample, 12 μg of 
digested genomic DNA was resolved overnight on a 0.7% 
agarose 1 x TBE gel. This gel was depurinated, denatured, 
and neutralized, followed by overnight capillary transfer 
to a nitrocellulose membrane. The membranes were pre-
hybridized for 1 hr with Church’s buffer, then hybridized 
with a γ-P32-endlabeled telomere probe in 4X SSC at 55°C 
overnight. Membranes were washed 3 times with 4X SSC 
and once with 4X SSC + 0.1% SDS, each for 30 min, 
exposed to a phosphorimaging screen, and detected and 
quantitated with a Typhoon phosphoimager.
Immunofluorescence and telomere FISH (IF-
FISH)
This assay was performed as described [94]. Briefly, 
cells (1 x 105) were plated on chamber slides, and allowed 
to grow for 24 hr. Cells were washed once with PBS, 
then fixed with 4% formaldehyde in 1X PBS. Blocking 
and RNaseA treatment (0.1 mg/mL) were performed in 
antibody dilution media (ABDIL; 20 mM Tris-HCl pH 7.4, 
0.2% fish gelatin, 2% BSA, 0.1% Triton X-100, 150 mM 
NaCl, and 0.1% sodium azide) at room temperature for 30 
min. Cells were stained with a 53BP1 antibody (Ab36823; 
Supplementary Table 2), which was diluted in ABDIL for 1 
hr, washed 3 times with 1X PBS + 0.1%Tween-20 (PBST), 
and incubated with an Alexa-488 goat IgG secondary 
antibody diluted in ABDIL for 1 hr. Cells were washed in 
PBST, fixed with 4% formaldehyde and prepared for FISH 
hybridization. A Telo-C PNA probe was hybridized to the 
slides at 80° in hybridization buffer (10 mM Tris-HCl pH 
7.4, 4 mM Na2HPO4, 0.5 mM citric acid, 1.25 mM MgCl2, 
0.25% blocking reagent and 70% formamide). Slides 
were washed, counterstained with DAPI, and mounted 
with ProLong Gold (ThermoFisher). Microscopy was 
performed with a Nikon-TiE deconvolution bright-field 
microscope with a 60X objective.
STELA and telomere fusion assay
Telomere length was determined using 17p STELA 
as described [94]. Briefly, DNA was extracted using 
proteinase K, RNase A, phenol/chloroform protocols and 
quantified by Hoechst 33258 fluorometry (Bio-Rad) before 
dilution to 10 ng/μL in 10 mM Tris-HCl, pH 7.5. A total of 
10 ng of DNA was further diluted to 250 pg/μL in a volume 
of 40 μL containing 1 μM Telorette2 linker and 1 mM Tris-
HCl, pH 7.5. Multiple polymerase chain reactions (PCRs; 
6 reactions per sample) were carried out for each test DNA 
in 10-μL volumes with 250 pg of DNA, 0.5 μM of the 
telomere-adjacent and Teltail primers, 75 mM Tris-HCl, 
pH 8.8, 20 mM (NH4)2SO4, 0.01% Tween-20, 1.5 mM 
MgCl2, and 0.5 U of a 10:1 mixture of Taq (ABGene) and 
Pwo polymerase (Roche Molecular Biochemicals). The 
reactions were cycled with an MJ PTC-225 thermocycler 
(MJ Research). The DNA fragments were resolved 
by 0.5% Tris acetate ethylenediaminetetraacetic acid 
agarose gel electrophoresis, and detected by Southern blot 
hybridization with random-primed α-33P–radiolabelled (GE 
Healthcare) TTAGGG repeat probe together with probes 
to detect the 1-kb (Stratagene) and 2.5-kb (Bio-Rad) 
molecular weight markers. The hybridized fragments were 
detected by phosphorimaging with a Molecular Dynamics 
Storm 860 phosphorimager (GE Healthcare). The 
molecular weights of the DNA fragments were calculated 
using the Phoretix 1D quantifier (Nonlinear Dynamics).
The telomere fusion assay was carried out as 
described [95]. PCR reactions were carried out each 
containing 100 ng of DNA with XpYpM, 17p6 and 21q1 
PCR primers. Fusion molecules were detected by Southern 
blotting and hybridization with the XpYp, 17p and 21q 
telomere-adjacent probes as described [95].
CONFLICTS OF INTEREST
EAH is a member of the scientific advisory boards 
for Horizon Discovery and Intellia Therapeutics.
FUNDING
Work in the Hendrickson laboratory was supported 
in part by grants from the NIH (GM088351) and the NCI 
(CA154461 and CA190492). Work in the Baird laboratory 
was supported by the Cancer Research UK (C17199/
A18246).
REFERENCES
1. Hayaishi O, Ueda K. Poly(ADP-ribose) and ADP-
ribosylation of proteins. Annu Rev Biochem. 1977; 
46:95-116.
2. Bock FJ, Chang P. New directions in poly(ADP-ribose) 
polymerase biology. FEBS J. 2016; 283:4017-4031.
3. Mangerich A, Burkle A. Pleiotropic cellular functions of 
PARP1 in longevity and aging: genome maintenance meets 
inflammation. Oxid Med Cell Longev. 2012; 2012:321653.
4. Wang ZQ, Auer B, Stingl L, Berghammer H, Haidacher 
D, Schweiger M, Wagner EF. Mice lacking ADPRT 
and poly(ADP-ribosyl)ation develop normally but are 
susceptible to skin disease. Genes Dev. 1995; 9:509-520.
5. Boltz KA, Jasti M, Townley JM, Shippen DE. Analysis of 
poly(ADP-Ribose) polymerases in Arabidopsis telomere 
biology. PLoS One. 2014; 9:e88872.
6. Miwa M, Hanai S, Poltronieri P, Uchida M, Uchida K. 
Functional analysis of poly(ADP-ribose) polymerase 
in Drosophila melanogaster. Mol Cell Biochem. 1999; 
193:103-107.
Oncotarget34834www.oncotarget.com
7. Hochegger H, Dejsuphong D, Fukushima T, Morrison C, 
Sonoda E, Schreiber V, Zhao GY, Saberi A, Masutani M, 
Adachi N, Koyama H, de Murcia G, Takeda S. Parp-1 
protects homologous recombination from interference 
by Ku and Ligase IV in vertebrate cells. EMBO J. 2006; 
25:1305-1314.
8. Helleday T. The underlying mechanism for the 
PARP and BRCA synthetic lethality: clearing up the 
misunderstandings. Mol Oncol. 2011; 5:387-393.
9. Krishnakumar R, Kraus WL. The PARP side of the nucleus: 
molecular actions, physiological outcomes, and clinical 
targets. Mol Cell. 2010; 39:8-24.
10. Gibson BA, Kraus WL. New insights into the molecular and 
cellular functions of poly(ADP-ribose) and PARPs. Nat Rev 
Mol Cell Biol. 2012; 13:411-424.
11. Godon C, Cordelieres FP, Biard D, Giocanti N, Megnin-
Chanet F, Hall J, Favaudon V. PARP inhibition versus 
PARP-1 silencing: different outcomes in terms of single-
strand break repair and radiation susceptibility. Nucleic 
Acids Res. 2008; 36:4454-4464.
12. Strom CE, Johansson F, Uhlen M, Szigyarto CA, Erixon 
K, Helleday T. Poly (ADP-ribose) polymerase (PARP) is 
not involved in base excision repair but PARP inhibition 
traps a single-strand intermediate. Nucleic Acids Res. 2011; 
39:3166-3175.
13. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow 
JH, Ji J, Takeda S, Pommier Y. Trapping of PARP1 and 
PARP2 by clinical PARP inhibitors. Cancer Res. 2012; 
72:5588-5599.
14. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, 
Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific 
killing of BRCA2-deficient tumours with inhibitors of 
poly(ADP-ribose) polymerase. Nature. 2005; 434:913-917.
15. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, 
Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights 
C, Martin NM, Jackson SP, Smith GC, et al. Targeting the 
DNA repair defect in BRCA mutant cells as a therapeutic 
strategy. Nature. 2005; 434:917-921.
16. Zimmermann M, Murina O, Reijns MAM, Agathanggelou 
A, Challis R, Tarnauskaite Z, Muir M, Fluteau A, Aregger 
M, McEwan A, Yuan W, Clarke M, Lambros MB, et 
al. CRISPR screens identify genomic ribonucleotides 
as a source of PARP-trapping lesions. Nature. 2018; 
559:285-289.
17. Rosen EM, Pishvaian MJ. Targeting the BRCA1/2 tumor 
suppressors. Curr Drug Targets. 2014; 15:17-31.
18. Min W, Bruhn C, Grigaravicius P, Zhou ZW, Li F, Kruger A, 
Siddeek B, Greulich KO, Popp O, Meisezahl C, Calkhoven 
CF, Burkle A, Xu X, et al. Poly(ADP-ribose) binding to 
Chk1 at stalled replication forks is required for S-phase 
checkpoint activation. Nat Commun. 2013; 4:2993.
19. Neelsen KJ, Lopes M. Replication fork reversal in 
eukaryotes: from dead end to dynamic response. Nat Rev 
Mol Cell Biol. 2015; 16:207-220.
20. Mijic S, Zellweger R, Chappidi N, Berti M, Jacobs K, Mutreja 
K, Ursich S, Ray Chaudhuri A, Nussenzweig A, Janscak P, 
Lopes M. Replication fork reversal triggers fork degradation 
in BRCA2-defective cells. Nat Commun. 2017; 8:859.
21. Margalef P, Kotsantis P, Borel V, Bellelli R, Panier S, 
Boulton SJ. Stabilization of reversed replication forks 
by telomerase drives telomere catastrophe. Cell. 2018; 
172:439-453.
22. Ray Chaudhuri A, Hashimoto Y, Herrador R, Neelsen KJ, 
Fachinetti D, Bermejo R, Cocito A, Costanzo V, Lopes 
M. Topoisomerase I poisoning results in PARP-mediated 
replication fork reversal. Nat Struct Mol Biol. 2012; 
19:417-423.
23. Maya-Mendoza A, Moudry P, Merchut-Maya JM, Lee M, 
Strauss R, Bartek J. High speed of fork progression induces 
DNA replication stress and genomic instability. Nature. 
2018; 559:279-284.
24. Fattah F, Lee EH, Weisensel N, Wang Y, Lichter N, 
Hendrickson EA. Ku regulates the non-homologous end 
joining pathway choice of DNA double-strand break repair 
in human somatic cells. PLoS Genet. 2010; 6:e1000855.
25. Oh S, Harvey A, Zimbric J, Wang Y, Nguyen T, Jackson 
PJ, Hendrickson EA. DNA ligase III and DNA ligase IV 
carry out genetically distinct forms of end joining in human 
somatic cells. DNA Repair (Amst). 2014; 21:97-110.
26. Shahar OD, Raghu Ram EV, Shimshoni E, Hareli S, 
Meshorer E, Goldberg M. Live imaging of induced and 
controlled DNA double-strand break formation reveals 
extremely low repair by homologous recombination in 
human cells. Oncogene. 2012; 31:3495-3504.
27. Pannunzio NR, Li S, Watanabe G, Lieber MR. Non-
homologous end joining often uses microhomology: 
implications for alternative end joining. DNA Repair 
(Amst). 2014; 17:74-80.
28. Iliakis G, Murmann T, Soni A. Alternative end-joining 
repair pathways are the ultimate backup for abrogated 
classical non-homologous end-joining and homologous 
recombination repair: Implications for the formation of 
chromosome translocations. Mutat Res Genet Toxicol 
Environ Mutagen. 2015; 793:166-175.
29. Ciccia A, Elledge SJ. The DNA damage response: making it 
safe to play with knives. Mol Cell. 2010; 40:179-204.
30. Simsek D, Brunet E, Wong SY, Katyal S, Gao Y, McKinnon 
PJ, Lou J, Zhang L, Li J, Rebar EJ, Gregory PD, Holmes 
MC, Jasin M. DNA ligase III promotes alternative 
nonhomologous end-joining during chromosomal 
translocation formation. PLoS Genet. 2011; 7:e1002080.
31. Ghezraoui H, Piganeau M, Renouf B, Renaud JB, 
Sallmyr A, Ruis B, Oh S, Tomkinson AE, Hendrickson 
EA, Giovannangeli C, Jasin M, Brunet E. Chromosomal 
translocations in human cells are generated by canonical 
nonhomologous end-joining. Mol Cell. 2014; 55:829-842.
32. Wang M, Wu W, Wu W, Rosidi B, Zhang L, Wang H, Iliakis 
G. PARP-1 and Ku compete for repair of DNA double 
Oncotarget34835www.oncotarget.com
strand breaks by distinct NHEJ pathways. Nucleic Acids 
Res. 2006; 34:6170-6182.
33. Wang H, Rosidi B, Perrault R, Wang M, Zhang L, 
Windhofer F, Iliakis G. DNA ligase III as a candidate 
component of backup pathways of nonhomologous end 
joining. Cancer Res. 2005; 65:4020-4030.
34. Audebert M, Salles B, Calsou P. Involvement of poly(ADP-
ribose) polymerase-1 and XRCC1/DNA ligase III in an 
alternative route for DNA double-strand breaks rejoining. 
J Biol Chem. 2004; 279:55117-55126.
35. Audebert M, Salles B, Calsou P. Effect of double-strand 
break DNA sequence on the PARP-1 NHEJ pathway. 
Biochem Biophys Res Commun. 2008; 369:982-988.
36. Doksani Y, de Lange T. The role of double-strand break 
repair pathways at functional and dysfunctional telomeres. 
Cold Spring Harb Perspect Biol. 2014; 6:a016576.
37. Hanahan D, Weinberg RA. Hallmarks of cancer: the next 
generation. Cell. 2011; 144:646-674.
38. Verdun RE, Karlseder J. Replication and protection of 
telomeres. Nature. 2007; 447:924-931.
39. Smith FW, Feigon J. Quadruplex structure of Oxytricha 
telomeric DNA oligonucleotides. Nature. 1992; 
356:164-168.
40. Parkinson GN, Lee MP, Neidle S. Crystal structure of 
parallel quadruplexes from human telomeric DNA. Nature. 
2002; 417:876-880.
41. Salvati E, Scarsella M, Porru M, Rizzo A, Iachettini S, 
Tentori L, Graziani G, D'Incalci M, Stevens MF, Orlandi 
A, Passeri D, Gilson E, Zupi G, et al. PARP1 is activated 
at telomeres upon G4 stabilization: possible target for 
telomere-based therapy. Oncogene. 2010; 29:6280-6293.
42. Wang X, Liu L, Montagna C, Ried T, Deng CX. 
Haploinsufficiency of Parp1 accelerates Brca1-associated 
centrosome amplification, telomere shortening, genetic 
instability, apoptosis, and embryonic lethality. Cell Death 
Differ. 2007; 14:924-931.
43. Gomez M, Wu J, Schreiber V, Dunlap J, Dantzer F, Wang 
Y, Liu Y. PARP1 Is a TRF2-associated poly(ADP-ribose)
polymerase and protects eroded telomeres. Mol Biol Cell. 
2006; 17:1686-1696.
44. Giannone RJ, McDonald HW, Hurst GB, Shen RF, Wang Y, 
Liu Y. The protein network surrounding the human telomere 
repeat binding factors TRF1, TRF2, and POT1. PLoS One. 
2010; 5:e12407.
45. d'Adda di Fagagna F, Hande MP, Tong WM, Lansdorp PM, 
Wang ZQ, Jackson SP. Functions of poly(ADP-ribose) 
polymerase in controlling telomere length and chromosomal 
stability. Nat Genet. 1999; 23:76-80.
46. Samper E, Goytisolo FA, Menissier-de Murcia J, Gonzalez-
Suarez E, Cigudosa JC, de Murcia G, Blasco MA. 
Normal telomere length and chromosomal end capping in 
poly(ADP-ribose) polymerase-deficient mice and primary 
cells despite increased chromosomal instability. J Cell Biol. 
2001; 154:49-60.
47. Beneke S, Cohausz O, Malanga M, Boukamp P, Althaus F, 
Burkle A. Rapid regulation of telomere length is mediated 
by poly(ADP-ribose) polymerase-1. Nucleic Acids Res. 
2008; 36:6309-6317.
48. Lee SS, Bohrson C, Pike AM, Wheelan SJ, Greider CW. 
ATM kinase is required for telomere elongation in mouse 
and human cells. Cell Rep. 2015; 13:1623-1632.
49. Hirata R, Chamberlain J, Dong R, Russell DW. Targeted 
transgene insertion into human chromosomes by 
adeno-associated virus vectors. Nat Biotechnol. 2002; 
20:735-738.
50. Dang LH, Chen F, Ying C, Chun SY, Knock SA, Appelman 
HD, Dang DT. CDX2 has tumorigenic potential in the 
human colon cancer cell lines LOVO and SW48. Oncogene. 
2006; 25:2264-2272.
51. Fattah FJ, Lichter NF, Fattah KR, Oh S, Hendrickson EA. 
Ku70, an essential gene, modulates the frequency of rAAV-
mediated gene targeting in human somatic cells. Proc Natl 
Acad Sci U S A. 2008; 105:8703-8708.
52. Ruis BL, Fattah KR, Hendrickson EA. The catalytic subunit 
of DNA-dependent protein kinase regulates proliferation, 
telomere length, and genomic stability in human somatic 
cells. Mol Cell Biol. 2008; 28:6182-6195.
53. Doherty JE, Huye LE, Yusa K, Zhou L, Craig NL, Wilson 
MH. Hyperactive piggyBac gene transfer in human cells 
and in vivo. Hum Gene Ther. 2012; 23:311-320.
54. Verkaik NS, Esveldt-van Lange RE, van Heemst D, 
Bruggenwirth HT, Hoeijmakers JH, Zdzienicka MZ, van 
Gent DC. Different types of V(D)J recombination and end-
joining defects in DNA double-strand break repair mutant 
mammalian cells. Eur J Immunol. 2002; 32:701-709.
55. Oh S, Wang Y, Zimbric J, Hendrickson EA. Human LIGIV 
is synthetically lethal with the loss of Rad54B-dependent 
recombination and is required for certain chromosome 
fusion events induced by telomere dysfunction. Nucleic 
Acids Res. 2013; 41:1734-1749.
56. Leahy JJ, Golding BT, Griffin RJ, Hardcastle IR, 
Richardson C, Rigoreau L, Smith GC. Identification of a 
highly potent and selective DNA-dependent protein kinase 
(DNA-PK) inhibitor (NU7441) by screening of chromenone 
libraries. Bioorg Med Chem Lett. 2004; 14:6083-6087.
57. Seluanov A, Mittelman D, Pereira-Smith OM, Wilson JH, 
Gorbunova V. DNA end joining becomes less efficient and 
more error-prone during cellular senescence. Proc Natl 
Acad Sci U S A. 2004; 101:7624-7629.
58. Janson C, Nyhan K, Murnane JP. Replication stress and 
telomere dysfunction are present in cultured human 
embryonic stem cells. Cytogenet Genome Res. 2015; 
146:251-260.
59. Huyen Y, Zgheib O, Ditullio RA Jr, Gorgoulis VG, 
Zacharatos P, Petty TJ, Sheston EA, Mellert HS, Stavridi 
ES, Halazonetis TD. Methylated lysine 79 of histone H3 
targets 53BP1 to DNA double-strand breaks. Nature. 2004; 
432:406-411.
Oncotarget34836www.oncotarget.com
60. Dimitrova N, Chen YC, Spector DL, de Lange T. 53BP1 
promotes non-homologous end joining of telomeres by 
increasing chromatin mobility. Nature. 2008; 456:524-528.
61. Hendrickson EA, Baird DM. Alternative end joining, clonal 
evolution, and escape from a telomere-driven crisis. Mol 
Cell Oncol. 2015; 2:e975623.
62. Jones RE, Oh S, Grimstead JW, Zimbric J, Roger L, Heppel 
NH, Ashelford KE, Liddiard K, Hendrickson EA, Baird 
DM. Escape from telomere-driven crisis is DNA ligase III 
dependent. Cell Rep. 2014; 8:1063-1076.
63. Liddiard K, Ruis B, Takasugi T, Harvey A, Ashelford KE, 
Hendrickson EA, Baird DM. Sister chromatid telomere 
fusions, but not NHEJ-mediated inter-chromosomal 
telomere fusions, occur independently of DNA ligases 3 
and 4. Genome Res. 2016; 26:588-600.
64. Baird DM, Rowson J, Wynford-Thomas D, Kipling D. 
Extensive allelic variation and ultrashort telomeres in 
senescent human cells. Nat Genet. 2003; 33:203-207.
65. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-
Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor 
MJ, Ashworth A, Carmichael J, Kaye SB, et al. Inhibition 
of poly(ADP-ribose) polymerase in tumors from BRCA 
mutation carriers. N Engl J Med. 2009; 361:123-134.
66. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur 
A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, 
Liu Q, Iorio F, Surdez D, et al. Systematic identification of 
genomic markers of drug sensitivity in cancer cells. Nature. 
2012; 483:570-575.
67. Gelmon KA, Hirte HW, Robidoux A, Tonkin KS, 
Tischkowitz M, Swenerton K, Huntsman D, Carmichael J, 
Macpherson E, Oza AM. Can we define tumors that will 
respond to PARP inhibitors? A phase II correlative study 
of olaparib in advanced serous ovarian cancer and triple-
negative breast cancer. Journal of Clinical Oncology. 2010; 
28:s3002.
68. Hendrickson EA. (2008). Gene targeting in human somatic 
cells. In: Conn PM, ed. Source Book of Models for 
Biomedical Research. (Totowa, NJ: Humana Press, Inc.), 
pp. 509-525.
69. Forbes SA, Beare D, Boutselakis H, Bamford S, Bindal N, 
Tate J, Cole CG, Ward S, Dawson E, Ponting L, Stefancsik 
R, Harsha B, Kok CY, et al. COSMIC: somatic cancer 
genetics at high-resolution. Nucleic Acids Res. 2017; 
45:D777-D783.
70. Gupte R, Liu Z, Kraus WL. PARPs and ADP-ribosylation: 
recent advances linking molecular functions to biological 
outcomes. Genes Dev. 2017; 31:101-126.
71. Dantzer F, Schreiber V, Niedergang C, Trucco C, Flatter E, 
De La Rubia G, Oliver J, Rolli V, Menissier-de Murcia J, de 
Murcia G. Involvement of poly(ADP-ribose) polymerase in 
base excision repair. Biochimie. 1999; 81:69-75.
72. de Murcia G, Menissier de Murcia J. Poly(ADP-ribose) 
polymerase: a molecular nick-sensor. Trends Biochem Sci. 
1994; 19:172-176.
73. Wahlberg E, Karlberg T, Kouznetsova E, Markova N, 
Macchiarulo A, Thorsell AG, Pol E, Frostell A, Ekblad T, 
Oncu D, Kull B, Robertson GM, Pellicciari R, et al. Family-
wide chemical profiling and structural analysis of PARP and 
tankyrase inhibitors. Nat Biotechnol. 2012; 30:283-288.
74. Menissier de Murcia J, Ricoul M, Tartier L, Niedergang 
C, Huber A, Dantzer F, Schreiber V, Ame JC, Dierich 
A, LeMeur M, Sabatier L, Chambon P, de Murcia G. 
Functional interaction between PARP-1 and PARP-2 in 
chromosome stability and embryonic development in 
mouse. EMBO J. 2003; 22:2255-2263.
75. Boehler C, Gauthier LR, Mortusewicz O, Biard DS, Saliou 
JM, Bresson A, Sanglier-Cianferani S, Smith S, Schreiber 
V, Boussin F, Dantzer F. Poly(ADP-ribose) polymerase 3 
(PARP3), a newcomer in cellular response to DNA damage 
and mitotic progression. Proc Natl Acad Sci U S A. 2011; 
108:2783-2788.
76. Langelier MF, Riccio AA, Pascal JM. PARP-2 and PARP-3 
are selectively activated by 5' phosphorylated DNA breaks 
through an allosteric regulatory mechanism shared with 
PARP-1. Nucleic Acids Res. 2014; 42:7762-7775.
77. Gibson BA, Zhang Y, Jiang H, Hussey KM, Shrimp JH, Lin 
H, Schwede F, Yu Y, Kraus WL. Chemical genetic discovery 
of PARP targets reveals a role for PARP-1 in transcription 
elongation. Science. 2016; 353:45-50.
78. Ceccaldi R, Rondinelli B, D'Andrea AD. Repair pathway 
choices and consequences at the double-strand break. 
Trends Cell Biol. 2016; 26:52-64.
79. Bennardo N, Cheng A, Huang N, Stark JM. Alternative-
NHEJ is a mechanistically distinct pathway of mammalian 
chromosome break repair. PLoS Genet. 2008; 4:e1000110.
80. Rass E, Grabarz A, Plo I, Gautier J, Bertrand P, Lopez BS. 
Role of Mre11 in chromosomal nonhomologous end joining 
in mammalian cells. Nat Struct Mol Biol. 2009; 16:819-824.
81. Badie S, Carlos AR, Folio C, Okamoto K, Bouwman 
P, Jonkers J, Tarsounas M. BRCA1 and CtIP promote 
alternative non-homologous end-joining at uncapped 
telomeres. EMBO J. 2015; 34:410-424.
82. Wang H, Zeng ZC, Bui TA, Sonoda E, Takata M, Takeda 
S, Iliakis G. Efficient rejoining of radiation-induced 
DNA double-strand breaks in vertebrate cells deficient 
in genes of the RAD52 epistasis group. Oncogene. 2001; 
20:2212-2224.
83. Mansour WY, Rhein T, Dahm-Daphi J. The alternative 
end-joining pathway for repair of DNA double-strand 
breaks requires PARP1 but is not dependent upon 
microhomologies. Nucleic Acids Res. 2010; 38:6065-6077.
84. Wray J, Williamson EA, Singh SB, Wu Y, Cogle CR, 
Weinstock DM, Zhang Y, Lee SH, Zhou D, Shao L, Hauer-
Jensen M, Pathak R, Klimek V, et al. PARP1 is required for 
chromosomal translocations. Blood. 2013; 121:4359-4365.
85. Soni A, Siemann M, Grabos M, Murmann T, Pantelias 
GE, Iliakis G. Requirement for Parp-1 and DNA ligases 
1 or 3 but not of Xrcc1 in chromosomal translocation 
Oncotarget34837www.oncotarget.com
formation by backup end joining. Nucleic Acids Res. 2014; 
42:6380-6392.
86. Sfeir A, de Lange T. Removal of shelterin reveals 
the telomere end-protection problem. Science. 2012; 
336:593-597.
87. Rai R, Chen Y, Lei M, Chang S. TRF2-RAP1 is required 
to protect telomeres from engaging in homologous 
recombination-mediated deletions and fusions. Nat 
Commun. 2016; 7:10881.
88. Chen Y, Yang Y, van Overbeek M, Donigian JR, Baciu P, de 
Lange T, Lei M. A shared docking motif in TRF1 and TRF2 
used for differential recruitment of telomeric proteins. 
Science. 2008; 319:1092-1096.
89. Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, 
Kurachi A, Beijersbergen RL, Knoll JH, Meyerson M, 
Weinberg RA. Inhibition of telomerase limits the growth of 
human cancer cells. Nat Med. 1999; 5:1164-1170.
90. Preto A, Singhrao SK, Haughton MF, Kipling D, Wynford-
Thomas D, Jones CJ. Telomere erosion triggers growth 
arrest but not cell death in human cancer cells retaining 
wild-type p53: implications for antitelomerase therapy. 
Oncogene. 2004; 23:4136-4145.
91. Khan IF, Hirata RK, Russell DW. AAV-mediated gene 
targeting methods for human cells. Nat Protoc. 2011; 
6:482-501.
92. Jasin M. Genetic manipulation of genomes with rare-cutting 
endonucleases. Trends Genet. 1996; 12:224-228.
93. Henson JD, Cao Y, Huschtscha LI, Chang AC, Au AY, 
Pickett HA, Reddel RR. DNA C-circles are specific 
and quantifiable markers of alternative-lengthening-of-
telomeres activity. Nat Biotechnol. 2009; 27:1181-1185.
94. Capper R, Britt-Compton B, Tankimanova M, Rowson J, 
Letsolo B, Man S, Haughton M, Baird DM. The nature of 
telomere fusion and a definition of the critical telomere 
length in human cells. Genes Dev. 2007; 21:2495-2508.
95. Letsolo BT, Rowson J, Baird DM. Fusion of short telomeres 
in human cells is characterized by extensive deletion and 
microhomology, and can result in complex rearrangements. 
Nucleic Acids Res. 2010; 38:1841-1852.
